Navigation Links
Liquid ventilation

To live we need to breathe. Prior to being born we carry this activity out through the placenta and subsequently by means of our lungs. In normal development, the lungs of the foetus are filled with amniotic liquid and, on being born, the first cry activates this respiration surface. But the main problem that premature babies have is that their lungs are not well formed. Moreover, they often lack surfactant, a compound formed by proteins and lipids that avoids the lungs folding in on themselves before the baby gets stronger.

The respirators usually employd in these cases provide artificial surfactant, but not always in sufficient amounts to provide correct therapy. In order to alleviate this situation, the Nautical School at the University of the Basque Country has developed a liquid respiration respirator.

The machine simulates placentary respiration by filling the lungs of the premature baby with liquid and then the respirator introduces and extracts the required quantity of liquid at a suitable respiratory rhythm. The amount of liquid administered is usually in the order of 10 millilitres per kilogram of the baby's weight.

Perfluorocarbons instead of air

Perfluorocarbon is used in liquid respiration, as it has a suitable surface tension in order to maintain the pulmonary structure and the fluorine has good properties for the transport of and interchange between blood and the gases, O2 and CO2. The respirator syringes introduce the oxygenated perfluorocarbon to the very last alveola. Here oxygen is released and carbon dioxide taken up in the same way as on the respiration surface. Then the respirator extracts part of the perfluorocarbon from the lungs and introduces the next oxygenated dose. The same machine carries out the removal of CO2 from the perfluorocarbon and adds oxygen to it.

Being full of liquid, the problems of pressure associated with conventional assisted respiration are avoided because the lungs of the premature baby suffer less stress and respire more easily.

However, this story does not have a happy ending. The respirator, for the moment, is no more than a prototype. In the experiments carried out at the Cruces hospital in Bilbao with artificial lungs and with animals, the results have been very good. It has even been applied successfully in more than 80 death-threatening situations in premature babies. But the perfluorocarbon for medical use is not available on the market. As premature babies need very small quantities and no commercial application for adults has been found, the patent-owning company has opted not to market it arguing that it lacks profitability. Thus, an industrial version of the liquid respirator is yet to be developed


'"/>

Source:Elhuyar Fundazioa


Related biology news :

1. Liquid crystals show promise in controlling embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology: